Skip to search formSkip to main contentSkip to account menu

formoterol

Known as: Formoterol [Chemical/Ingredient], Eformoterol, 2'-Hydroxy-5'-(1-hydroxy-2-((P-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide 
A long-acting beta-adrenergic receptor agonist with bronchodilator activity. Formoterol selectively binds to beta-2 adrenergic receptors in bronchial… 
National Institutes of Health

Related topics

Related topics

17 relations
Acute DiseaseAdrenergic beta2-Agonists [MoA]AsthmaAsthma, Exercise-Induced

Narrower (8)

DuleraForadilOxisPerforomist

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Formoterol restores mitochondrial and renal function after ischemia-reperfusion injury.
Mitochondrial biogenesis may be an adaptive response necessary for meeting the increased metabolic and energy demands during… 
Highly Cited
2010
Highly Cited
2010
Overall asthma control: the relationship between current control and future risk.
Review
2010
Review
2010
The FDA and safe use of long-acting beta-agonists in the treatment of asthma.
The FDA has conducted a comprehensive review of the benefits and risks of using LABAs to treat asthma. Drs. Badrul Chowdhury and… 
Review
2007
Review
2007
Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies
Review
2005
Review
2005
Past, present and future--beta2-adrenoceptor agonists in asthma management.
Highly Cited
2002
Highly Cited
2002
Interaction between glucocorticoids and β2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling
Highly Cited
1998
Highly Cited
1998
Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia.
OBJECTIVE There are several reports of documented adverse cardiac effects during treatment with beta-agonists. Since one should… 
Highly Cited
1997
Highly Cited
1997
Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
Salmeterol and formoterol are two long-acting beta2-agonists for inhalation, currently being used in clinical practice. The aim… 
Highly Cited
1996
Highly Cited
1996
Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action.
We evaluated the profile of the bronchodilatory effect of three inhaled beta2-agonists, 24 microg formoterol, 50 microg… 
Highly Cited
1995
Highly Cited
1995
Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients.
BACKGROUND--There is controversy as to the role of long acting beta 2 agonists such as eformoterol and, in particular, whether… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)